Skip to main content

Table 2 Patients characteristics

From: “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis

Variable

 

Patients (n = 13)

HCV Genotype 1

 

13 (100%)

Fibrosis stage 0-1

 

1 (8%)

Fibrosis stage 2

 

3 (23%)

Fibrosis stage 3

 

3 (23%)

Fibrosis stage 4

 

6 (46%)

Gender

Male

8 (62%)

 

Female

5 (38%)

Mean age in years (range)

 

49 (36–63)

Transmission

IDU1

6 (46%)

 

Blood products

2 (15%)

 

Unsafe sex

1 (8%)

 

Unsafe tattooing

1 (8%)

 

Unknown

3 (23%)

Opioid substitution

 

3 (23%)

Multimorbidity2

 

4 (30%)

First diagnosed mean years (range)

 

12.5 (1.5 - 28)

Treatment experience

Naive

5 (38%)

 

Dual therapy 1×

7 (54%)

 

Dual therapy 2×

1 (8%)

Protease inhibitor

Telaprevir

9 (70%)

 

Boceprevir

4 (30%)

Status proteaseinhibitor therapy

Ongoing

5 (38%)

Completed

5 (38%)

Discontinued3

3 (23%)

Residence situation

With Partner/Family

8 (62%)

 

alone

3 (23%)

 

Institution4

2 (15%)

Occupation before triple therapy

 

10 (80%)

Job related working ability during triple therapy

0-25%

5 (50%)

 

26-50%

1 (10%)

 

51-75%

1 (10%)

 

76-100%

3 (30%)

  1. 1Intravenous drug user.
  2. 2One patient with HIV, haemophilia, Depression or Schizophrenia.
  3. 3Two patients due to neutropenia, one patient due to unbearable side effects.
  4. 4Mental hospital, assisted accommodation.